REFACTO AF

AU:B2 B02BD02(WHO) UK:POM(Prescription only)In general: ℞ (Prescription only) 284036-24-4 DB13999 none 113E3Z3CJJ D08232 ChEMBL2109137 Moroctocog alfa(trade nameReFactoin the EU) is a recombinantantihemophilic factorgenetically engineered fromChinese hamster ovary(CHO) cell line. Chemically it is aglycoprotein.It is manufactured byGenetics Institute, Inc.and used to control and prevent hemorrhagic bleeding and prophylaxis associated with surgery or to reduce the number of spontaneous bleeding episodes in patients withhemophilia A.It is partially a recombinant coagulationfactor VIIIsince it has an amino acid sequence which compares to the 90 + 80 kDa form of factor VIII (BDDrFVIII).It also hasposttranslational modificationswhich are similar to those of the plasma-derived molecule. It can not prevent hemorrhagic bleeding associated withvon Willebrand's diseasesince it is not avon Willebrand factor. The most common side effects include headache, cough, pain in the joints and fever.People may also develop antibodies against factor VIII medicines such as moroctocog alfa.These are known as inhibitors as they can prevent the medicine from working effectively, which may result in a loss of bleeding control.Uncommonly, people may also develop allergic reactions. People with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems, such as bleeding in the joints, muscles and internal organs.Moroctocog alfa works in the body in the same way as human factor VIII.It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding. The human coagulation factor VIII in moroctocog alfa is not extracted from human blood but is produced by a method known as 'recombinant DNA technology': it is made by a cell that has received a gene (DNA), which makes it able to produce human coagulation factor VIII.